Company Overview

Ekso Bionics Holdings, Inc. is a publicly traded medical device company focused on the development and commercialization of wearable robotic exoskeletons designed to enhance human mobility and physical capabilities. The company operates primarily within the healthcare and medical technology industries, with a strategic emphasis on neurorehabilitation and mobility restoration for patients with neurological and musculoskeletal conditions. Ekso Bionics’ products are used in clinical settings to support rehabilitation following stroke, spinal cord injury, and other mobility-impairing conditions.

The company’s core revenue is generated from the sale and servicing of its medical exoskeleton devices, particularly systems designed for use by rehabilitation hospitals and therapy centers. Ekso Bionics positions itself as a clinically validated provider with FDA-cleared technologies and an installed base across leading rehabilitation institutions. Founded in the early 2000s, the company evolved from a defense and industrial robotics concept into a healthcare-focused organization, ultimately narrowing its strategy to prioritize medical applications following divestitures and operational restructuring over the past decade.

Business Operations

Ekso Bionics conducts its business primarily through a single operating segment focused on Healthcare Exoskeletons, which includes robotic devices that assist patients and clinicians during gait training and upper extremity rehabilitation. Key products include EksoNR for lower-extremity rehabilitation and EksoUE for upper-limb therapy. Revenue is derived from direct device sales, service contracts, and training-related support provided to clinical customers.

Historically, the company also operated an Industrial Exoskeletons segment, offering devices intended to reduce workplace injury and fatigue. However, based on public disclosures, Ekso Bionics has largely exited or deemphasized this business line to concentrate resources on healthcare applications. Operations are supported by proprietary robotics technology, software, and clinical data, with sales conducted through a combination of direct sales personnel and international distributors.

Strategic Position & Investments

Ekso Bionics’ strategic direction centers on expanding adoption of robotic-assisted rehabilitation by demonstrating clinical efficacy, improving reimbursement pathways, and increasing penetration within established rehabilitation networks. Growth initiatives have focused on product enhancements, expanded clinical indications, and strengthening relationships with hospital systems and rehabilitation providers.

A significant strategic milestone was the divestiture of Indego, its personal mobility exoskeleton business, which was acquired by Parker Hannifin Corporation. This transaction reinforced Ekso Bionics’ focus on clinical rehabilitation rather than consumer or take-home mobility devices. The company continues to invest in next-generation exoskeleton technologies, software integration, and clinical research to support broader adoption and long-term differentiation within the rehabilitation robotics sector.

Geographic Footprint

Ekso Bionics is headquartered in Richmond, California, and conducts its primary operations from the United States. The company maintains a meaningful presence across North America through direct sales and clinical partnerships with rehabilitation hospitals and veterans’ healthcare systems.

Internationally, Ekso Bionics has an established footprint in Europe and parts of Asia-Pacific, supported by distributor relationships and regulatory approvals in multiple countries. These international markets contribute to revenue diversification and provide exposure to regions with increasing demand for advanced rehabilitation technologies and aging population demographics.

Leadership & Governance

Ekso Bionics was founded by Russell Angold and Nathan Harding, whose early work in human augmentation and robotics laid the foundation for the company’s technology platform. The current leadership team emphasizes disciplined execution, clinical validation, and financial sustainability as core elements of its operating philosophy.

Key executives include:

• Scott Davis – Chief Executive Officer
• Shefali Kumar – Chief Financial Officer
• Bryan Stewart – Chief Technology Officer
• Steve Sherman – Senior Vice President, Sales and Marketing

The leadership team operates under a governance framework typical of U.S.-listed medical device companies, with oversight provided by an independent board of directors and reporting obligations under SEC filings, including annual and quarterly reports.

Verification Requirements

All information presented is based on publicly available disclosures, including SEC filings, investor communications, and coverage by established financial and medical technology publications. Where business lines or strategic initiatives have changed over time, descriptions reflect the most consistently reported and corroborated information. If discrepancies exist across sources, interpretations are limited to verifiable consensus, and no speculative assertions have been included.